Company / Return on Assets (ROA)
Inhibikase Therapeutics, Inc. Return on Assets (ROA) History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-19.3%
FY2024
5-year range
-124.4% / -6.7%
FY2021-FY2024
Trend
+84.5%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Return on Assets (ROA) returned to growth in FY2024 after 2 years of decline, reaching -19.3%.
Based on SEC 10-K filings.
-19.3% in FY2024 with a 3-year CAGR of -12.6%.
Improved from -59.3% to -19.3% over the past 2 years.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -12.6pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2024, return on assets (roa) increased 84.5% year-over-year.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -19.3% | +84.5% |
| FY2023 | -124.4% | -109.9% |
| FY2022 | -59.3% | -783.8% |
| FY2021 | -6.7% | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026